Haleon plc (NYSE:HLN) Shares Sold by Banco Santander S.A.

Banco Santander S.A. trimmed its stake in shares of Haleon plc (NYSE:HLN) by 15.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 109,240 shares of the company’s stock after selling 19,960 shares during the quarter. Banco Santander S.A.’s holdings in Haleon were worth $1,042,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Haleon during the 4th quarter worth approximately $39,628,000. Mesirow Financial Investment Management Inc. raised its position in shares of Haleon by 104.3% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 28,112 shares of the company’s stock worth $268,000 after purchasing an additional 14,349 shares during the period. West Family Investments Inc. raised its position in shares of Haleon by 16.8% during the 4th quarter. West Family Investments Inc. now owns 15,746 shares of the company’s stock worth $150,000 after purchasing an additional 2,265 shares during the period. Callan Family Office LLC acquired a new stake in Haleon in the 4th quarter valued at approximately $1,970,000. Finally, Vestmark Advisory Solutions Inc. increased its position in Haleon by 53.2% in the 4th quarter. Vestmark Advisory Solutions Inc. now owns 62,420 shares of the company’s stock valued at $595,000 after acquiring an additional 21,673 shares during the period. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. HSBC restated a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Hsbc Global Res cut Haleon from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Finally, Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Five analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Haleon has an average rating of “Moderate Buy” and a consensus target price of $10.95.

Haleon Stock Up 0.5 %

Shares of HLN stock opened at $10.45 on Monday. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80. The stock has a market cap of $47.29 billion, a PE ratio of 30.72, a price-to-earnings-growth ratio of 2.82 and a beta of 0.25. The business’s fifty day moving average is $9.68 and its 200-day moving average is $9.86. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

Haleon (NYSE:HLN) last issued its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The company had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Equities analysts expect that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The company also recently declared a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be given a dividend of $0.1166 per share. The ex-dividend date is Friday, April 25th. This is a boost from Haleon’s previous — dividend of $0.05. This represents a dividend yield of 1.6%. Haleon’s dividend payout ratio (DPR) is 58.97%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.